Role of phospholipase A2 in prostate cancer

Binil Eldhose; Claire Wilson

doi:10.1016/B978-0-323-95697-0.00027-3

Role of phospholipase A₂ in prostate cancer

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

Prostate cancer remains one of the leading causes of death in men. Novel therapeutic approaches are necessary to enhance overall outcomes and survival due to the rise of castration-resistant prostate cancer (CRPC) and insensitivity to androgen-deprivation therapies. Men with hormone-refractory prostate cancer are not responding well to current treatments, which emphasizes the significance of finding the molecular factors that contribute to prostate cancer growth and survival that may be employed as therapeutic targets. Compared to existing chemotherapy regimens, such targeted therapies have the potential to considerably reduce toxicity while improving cancer progression. The discovery that prostate cancer cells contain phospholipase A2 (PLA2) and the demonstration that PLA2 inhibition can limit cancer cell proliferation in vitro and in vivo make PLA2 a promising therapeutic target.

Original language	English
Title of host publication	Phospholipases in Physiology and Pathology
Subtitle of host publication	Volumes 1-7
Publisher	Elsevier
Pages	V3-39-V3-54
Volume	3
ISBN (Electronic)	9780323956871
ISBN (Print)	9780323956888
DOIs	https://doi.org/10.1016/B978-0-323-95697-0.00027-3
State	Published - 1 Jan 2023
Externally published	Yes

Keywords

Androgen receptor
Arachidonic acid
Biomarker
ERG
Glycerophospholipids
Lysophospholipids
Metastatic prostate cancer
Phospholipase A
Prostate cancer
Prostate specific antigen

Access to Document

10.1016/B978-0-323-95697-0.00027-3

Cite this

@inbook{0b0560353b4643dba8c04371b308de84,

title = "Role of phospholipase A2 in prostate cancer",

abstract = "Prostate cancer remains one of the leading causes of death in men. Novel therapeutic approaches are necessary to enhance overall outcomes and survival due to the rise of castration-resistant prostate cancer (CRPC) and insensitivity to androgen-deprivation therapies. Men with hormone-refractory prostate cancer are not responding well to current treatments, which emphasizes the significance of finding the molecular factors that contribute to prostate cancer growth and survival that may be employed as therapeutic targets. Compared to existing chemotherapy regimens, such targeted therapies have the potential to considerably reduce toxicity while improving cancer progression. The discovery that prostate cancer cells contain phospholipase A2 (PLA2) and the demonstration that PLA2 inhibition can limit cancer cell proliferation in vitro and in vivo make PLA2 a promising therapeutic target.",

keywords = "Androgen receptor, Arachidonic acid, Biomarker, ERG, Glycerophospholipids, Lysophospholipids, Metastatic prostate cancer, Phospholipase A, Prostate cancer, Prostate specific antigen",

author = "Binil Eldhose and Claire Wilson",

year = "2023",

month = jan,

day = "1",

doi = "10.1016/B978-0-323-95697-0.00027-3",

language = "English",

isbn = "9780323956888",

volume = "3",

pages = "V3--39--V3--54",

booktitle = "Phospholipases in Physiology and Pathology",

publisher = "Elsevier",

}

TY - CHAP

T1 - Role of phospholipase A2 in prostate cancer

AU - Eldhose, Binil

AU - Wilson, Claire

PY - 2023/1/1

Y1 - 2023/1/1

N2 - Prostate cancer remains one of the leading causes of death in men. Novel therapeutic approaches are necessary to enhance overall outcomes and survival due to the rise of castration-resistant prostate cancer (CRPC) and insensitivity to androgen-deprivation therapies. Men with hormone-refractory prostate cancer are not responding well to current treatments, which emphasizes the significance of finding the molecular factors that contribute to prostate cancer growth and survival that may be employed as therapeutic targets. Compared to existing chemotherapy regimens, such targeted therapies have the potential to considerably reduce toxicity while improving cancer progression. The discovery that prostate cancer cells contain phospholipase A2 (PLA2) and the demonstration that PLA2 inhibition can limit cancer cell proliferation in vitro and in vivo make PLA2 a promising therapeutic target.

AB - Prostate cancer remains one of the leading causes of death in men. Novel therapeutic approaches are necessary to enhance overall outcomes and survival due to the rise of castration-resistant prostate cancer (CRPC) and insensitivity to androgen-deprivation therapies. Men with hormone-refractory prostate cancer are not responding well to current treatments, which emphasizes the significance of finding the molecular factors that contribute to prostate cancer growth and survival that may be employed as therapeutic targets. Compared to existing chemotherapy regimens, such targeted therapies have the potential to considerably reduce toxicity while improving cancer progression. The discovery that prostate cancer cells contain phospholipase A2 (PLA2) and the demonstration that PLA2 inhibition can limit cancer cell proliferation in vitro and in vivo make PLA2 a promising therapeutic target.

KW - Androgen receptor

KW - Arachidonic acid

KW - Biomarker

KW - ERG

KW - Glycerophospholipids

KW - Lysophospholipids

KW - Metastatic prostate cancer

KW - Phospholipase A

KW - Prostate cancer

KW - Prostate specific antigen

UR - http://www.scopus.com/inward/record.url?scp=85176877519&partnerID=8YFLogxK

U2 - 10.1016/B978-0-323-95697-0.00027-3

DO - 10.1016/B978-0-323-95697-0.00027-3

M3 - Chapter

AN - SCOPUS:85176877519

SN - 9780323956888

VL - 3

SP - V3-39-V3-54

BT - Phospholipases in Physiology and Pathology

PB - Elsevier

ER -